Product Program year 2023 Source: CMS Open Payments

Vonjo

Drug Hematology

NDC 72482-100-12

Open in the dashboard

General payments

$1,880,798

5,985 payments

Research payments

$2,294,915

128 payments

Through program year 2023, $1,880,798 in general payments and $2,294,915 in research payments were reported against Vonjo (Hematology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2023 General $1,191,739 4,095
2023 Research $1,942,938 93
2022 General $689,059 1,890
2022 Research $351,977 35

Breakdown

Who paid General payments · program years 2022–2023
  1. CTI BioPharma Corp. $1,880,798 5,985 payments
Top recipients General payments · program year 2023
  1. Rush University Medical Center Teaching hospital · IL $78,435 7% · 1 payment
  2. Karolina Faysman Nurse Practitioner, Adult Health · Los Angeles, CA $70,902 6% · 52 payments
  3. Jamie Koprivnikar Medical Oncology · Hackensack, NJ $67,643 6% · 50 payments
  4. James McCloskey Medical Oncology · Hackensack, NJ $47,071 4% · 36 payments
  5. Mojtaba Akhtari Hematology & Oncology · Omaha, NE $42,172 4% · 27 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2023.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2023
  1. Hematology & Oncology Internal Medicine $362,267 37% · 999 practitioners
  2. Medical Oncology Internal Medicine $242,883 25% · 337 practitioners
  3. Hematology Internal Medicine $117,580 12% · 45 practitioners
  4. Nurse Practitioner, Adult Health Nurse Practitioner $96,889 10% · 98 practitioners
  5. Nurse Practitioner $54,723 6% · 232 practitioners

The top 5 of 48 specialties; each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2023
  1. California $171,386 14% · 202 recipients
  2. Texas $131,113 11% · 308 recipients
  3. New Jersey $125,375 11% · 116 recipients
  4. Illinois $83,453 7% · 90 recipients
  5. Arizona $68,271 6% · 104 recipients

The top 5 of 48 states; each share is of general payments naming this product in 2023 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

1,946

Prescriptions dispensed, refills included

Drug cost

$44,146,322

Paid at the pharmacy, in all

Prescribers

132

With 11 or more claims of it

Medicare Part D drugs matched to Vonjo, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Vonjo Pacritinib Citrate Same name 132 1,946 $44,146,322

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Pankit Vachhani Hematology-Oncology AL 41 $981,207 $5,685
Ashwin Kishtagari Hematology TN 40 $1,026,982 $16,344
Christopher Benton Medical Oncology CO 39 $759,641 $22
Anthony Hunter Hematology GA 33 $745,877 None on record
Brandi Reeves Hematology-Oncology NC 31 $764,134 $125

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
5,985 general · 128 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record